BMS 986094

Drug Profile

BMS 986094

Alternative Names: BMS-986094; HCV NS5b polymerase inhibitors - Inhibitex; HCV polymerase inhibitors - Inhibitex; INX-08189; INX-189

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cardiff University; Katholieke Universiteit Leuven; University of Georgia
  • Developer Inhibitex
  • Class Antivirals; Nucleosides; Purine nucleosides
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 30 Apr 2013 Duke University initiates a longitudinal study evaluating the incidence of cardiac and renal dysfunction in patients exposed to BMS 986094 in USA (NCT01846494)
  • 23 Aug 2012 Discontinued - Phase-I/II for Hepatitis C in Puerto Rico (PO)
  • 23 Aug 2012 Discontinued - Phase-II for Hepatitis C in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top